Non-specific Inflammation and Host Resistance Against Pathogens

Fauve, Robert M.; Hevin, M. Brigitte; Fontan, Élisabeth

doi:10.1016/b978-0-08-026384-7.50031-8

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the ways in which tumour cells can evade or subvert host defences is the production of soluble factors which interfere with the expression of cell-mediated immunity (CMI), including macrophage function (7)(8)(9)(10)(11)(12). In studies in this laboratory, all tumours tested, regardless of type or Abbreviations used in this paper: CMI, cell-mediated immunity; con-A.…”

Section: Introductionmentioning

confidence: 99%

Festschrift Inhibition of cell‐mediated immunity by tumour cell products: Depression of interleukin‐2 production and responses to interleukin‐2 by mouse spleen cells

Nelson

Nelson²

1988

Immunol Cell Biol

View full text Add to dashboard Cite

Summary Supernatants from cultures of mouse and human tumour cells inhibited the production of interleukin‐2 (IL‐2) by stimulated mouse spleen cells. The tumour cells tested, all of which were active, included a mouse and a human melanoma, three methylcholanthrene‐induced fibrosarcomas of mice, and human HeLa cells. Supernatants from normal mouse and human fibroblasts were inactive. Inhibition was dose‐dependent. Spleen cells from aged mice were more susceptible to inhibition than spleen cells from young mice. When tumour cell culture supernatants were fractionated on Sephacryl S‐300, two peaks of activity were found, with apparent molecular weights of approximately 50 and 18 kD. Supernatants from tumour cell and fibroblast cultures caused variable, but generally weak, inhibition of responses of lymphoblasts to IL‐2. It is suggested that inhibition of IL‐2 production may be an important mode of action of tumour cell products that inhibit cell‐mediated immunity.

show abstract